Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects.

ABSTRACT: Hereditary amyloid transthyretin (ATTRv) amyloidosis with polyneuropathy is a progressive disease that is transmitted as an autosomal dominant trait and characterized by multiple organ failure, including axonal sensory-motor neuropathy, cardiac involvement, and autonomic dysfunction. Liver transplantation (LT) and combined heart-liver transplantation, introduced in the 1990s, have been the only therapies for almost two decades. In 2011, tafamidis meglumine became the first specific drug approved by regulatory agencies, since then the attention toward this disease has progressively increased and several drugs with different mechanisms of action are now available. This review describes the drugs already on the market, those that have shown interesting results although not yet approved, and t

SUBMITTER: Russo M 

PROVIDER: S-EPMC7763612 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature